US$ 21.69
oral glp-1 agonist approved Comparing Ozempic, Wegovy and Other Drugs novo nordisk glp-1 receptor agonist
Description
oromucosal, buccal, gingival and sublingual
Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial)

Grateful to my mentors, co-authors, and the journal editorial team for their support throughout this journey

LTP, long-term enhancement
One study (SURPASS-2) specifically compared Mounjaro 5 mg, 10 mg, and 15 mg to low-dose semaglutide (1 mg) in people with type 2 diabetes
